GV leads Series A round for Verve Therapeutics
Cambridge, Massachusetts-based Verve Therapeutics, a next-generation cardiovascular company, has raised $58.5 million in Series A funding. GV led the round with participation from ARCH Venture Partners, F-Prime Capital and Biomatics Capital.
7 May 2019•1 min read
